SAN FRANCISCO--(BUSINESS WIRE)--Ossium Health, an innovative bioengineering company that established a first-of-its-kind bone marrow banking platform, today announced the appointment of Lauren Barnes to its Board of Directors. Barnes brings extensive experience in healthcare product commercialization, significantly bolstering Ossium’s capacity to drive growth and deliver life-changing solutions for patients suffering from hematologic diseases, organ transplant rejection, and musculoskeletal defects.
“Lauren’s expertise and proven track record in biopharmaceutical commercialization are invaluable assets,” said Kevin Caldwell, Ossium’s CEO, Co-Founder & President. “Her insights and guidance will be instrumental in bringing our products to the patients that need them as we transition to a commercial company.”
Barnes boasts a distinguished career in commercialization, pricing, reimbursement, market access, and managed markets for healthcare products spanning various market segments. She currently serves as Senior Vice President of Strategic Market Development & Access at Blueprint Medicines, a global commercial-stage precision therapy company with expertise in molecular targeting, drug design, and translational science. Previously, she held positions as Vice President of Managed Markets at Vertex Pharmaceuticals, Senior Vice President of Product Reimbursement & Commercialization at Avalere Health, and Director of Reimbursement at Amgen. In addition, Barnes serves as a board member for Ascelia Pharma AB, a Swedish oncology drug development company with two late-stage drug candidates, and she recently completed her time as Chair of the Board of Directors for the non-profit Cancer Support Community.
“I am incredibly excited to join Ossium’s Board of Directors at this pivotal moment in the company’s journey,” said Barnes. “Ossium’s dedication to developing innovative technologies that address the unmet needs of the blood cancer community resonates deeply with me. I look forward to helping Ossium accelerate their success and impact countless lives as they increase bone marrow accessibility and improve the safety of these transplant procedures.”
Barnes’ appointment underscores Ossium’s dedication to assembling a world-class Board of Directors equipped with diverse perspectives and proven expertise. Her expertise in commercialization and market access strategy at biopharmaceutical companies in various stages of development complements the expertise of the incumbent board members and will further propel Ossium toward its ambitious goals.
About Ossium Health
Ossium Health is a bioengineering company that leverages its proprietary organ donor bone marrow banking platform to develop stem cell therapies for patients with life-threatening blood and immune diseases. Founded in 2016, the company is led by Kevin Caldwell, CEO, Co-Founder & President, and Erik Woods, Chief Science Officer, Co-Founder & EVP. Ossium Health’s manufacturing facility is registered with the FDA and its laboratory is certified under the Clinical Laboratory Improvement Amendment (CLIA).
